Abstract: Transfer sets are disclosed in the present patent. The transfer set provides a connection between a source of peritoneal dialysis fluid and a patient for whom peritoneal dialysis has been prescribed. The transfer sets disclosed herein are smaller and provide a more compact and convenient device by which a dialysis patient controls the flow of dialysis fluid to and from the peritoneum of the patient. The devices are more compact and convenient because they include more convenient mechanisms for starting and stopping flow of the dialysis fluid. It is also easy to determine whether the mechanism is in a closed or open configuration by simply looking at the mechanism.

Abstract: A system and method for automatically adjusting a Continuous Cycling Peritoneal Dialysis (“CCPD”) therapy to minimize the potential for excess intra-peritoneal volume. The adjustments are made at the end of the drain, just prior to the next fill. The adjustments short the next fill, if necessary, to limit the intra-peritoneal volume, add a cycle, if necessary, to use all of the available dialysis solution and will average the remaining dwell time to maximize the therapeutic benefit of the therapy in the allotted time. In another embodiment, a tidal therapy using trended patient UF data is provided.

Abstract: A medical fluid or dialysis system includes an auto-connection mechanism that connects connectors from the supply bags to dialysis cassette ports or cassette supply lines. The system provides for multiple, e.g., four, supply bags, which can be connected to a manifold of the auto-connection mechanism. Tip protecting caps that protect the supply line ends and cassette ports or cassette supply line ends are made to be compatible with the auto-connection mechanism. The auto-connection mechanism removes all the caps and connects the supply lines to the cassette. At least one roller occluder is provided that occludes the supply tubing prior to the tip protecting caps being removed. The roller occludes prevent medical dialysis fluid from spilling out of the supply lines between the time that the caps are removed and connection to the cassette is made.

Abstract: A system for monitoring water quality for dialysis, dialysis fluids, and body fluids treated by dialysis fluids, is disclosed. The system uses microelectromechanical systems (MEMS) sensors for detecting impurities in input water or dialysis fluid, and in the prepared dialysate. These sensors may also be used to monitor and check the blood of the patient being treated. These sensors include ion-selective sensors, for ions such as ammonium or calcium, and also include amperometric array sensors, suitable for ions from chlorine or chloramines, e.g., chloride. These sensors assist in the monitoring of water supplies from a city water main or well. The sensors may be used in conjunction with systems for preparing dialysate solutions from water for use at home or elsewhere.

Abstract: Dialysis is enhanced by using nanoclay sorbents to better absorb body wastes in a flow-through system. Nanoclay sorbents, using montmorillonite, bentonite, and other clays, absorb significantly more ammonium, phosphate, and creatinine, and the like, than conventional sorbents. The clays may be used in wearable systems, such as a wearable peritoneal dialysis system, in which the dialysis fluid is circulated through a filter with nanoclay sorbents. Waste products are absorbed by the nanoclays and the dialysis fluid is recycled to the patient's peritoneum. Using the ion-exchange capability of the nanoclays, waste ions in the dialysis fluid are replaced with desirable ions, such as calcium, magnesium, and bicarbonate. The nanoclay sorbents are also useful for refreshing dialysis fluid used in hemodialysis and thus reducing the quantity of dialysis fluid needed for hemodialysis.

Abstract: A peritoneal dialysis system includes: a dialysis fluid container associated with an identifier; a reader for reading the identifier; a signal transmitter for communicating data based on the identifier; and a patient transfer set for semi-permanent connection to a patient, the patient transfer set including: (i) a signal receiver for receiving the data sent by the signal transmitter, (ii) an output device for communicating with the patient, and (iii) electronics configured to received the data and command the output device to communicate with the patient accordingly.

Abstract: Peritoneal dialysis therapy outcomes have been calculated for a variety of dwell times of peritoneal dialysis fluids in the peritoneal cavities of dialysis patients using kinetic modeling. The length of dwell time should not be the same for every patient, but should vary according to the patient condition and needs. Some patients have a potential for expressing greater ultrafiltrate into the dialysis fluid, and these patients can benefit from a longer dwell time, whereas other patients with less potential will not benefit from a longer dwell time. An optimal or peak time is observed for each peritoneal dialysis therapy outcome, such as ultrafiltrate volume rate, urea clearance (Kt/V), and creatinine clearance, while minimizing hydrocarbon absorption. These values and input parameters can be used to tailor the peritoneal dialysis dwell time for each patient, estimating the peak dwell time that will yield the best therapy outcome for each patient.

Abstract: A peritoneal dialysis flow control device in one embodiment includes: (i) a first cap including a first medical fluid line connection and a second medical fluid line connection; (ii) a gasket mated with the first cap where the gasket defines a first aperture in fluid communication with a first port and a second aperture in fluid communication with a second port; and (iii) a second cap including a third medical fluid line connection where the second cap is sealed rotatably to the gasket.

Abstract: A system and method for balancing flows of renal replacement fluid is disclosed. The method uses pressure controls and pressure sensing devices to more precisely meter and balance the flow of fresh dialysate and spent dialysate. The balancing system may use one or two balancing devices, such as a balance tube, a tortuous path, or a balance chamber.

Abstract: Films containing microlayer structures are provided. In a general embodiment, the present disclosure provides an autoclavable film containing a first microlayer of a heat resistant polymer and a second microlayer of a flexible polymer attached to the first microlayer. Each of the first microlayer and the second microlayer has a thickness ranging between about 0.01 microns and about 10 microns.

Abstract: Systems and methods manually process blood and blood components in sterile, closed environments, which further condition the blood components for subsequent pathogen inactivation processes. The systems and methods mate the manual collection of random donor platelet units with the creation of larger therapeutic doses of platelets targeted to undergo pathogen inactivation prior to long term storage and/or transfusion.

Abstract: A kidney failure therapy system includes: (a) a dilaysate supply; (b) at least one valve actuator; (c) at least one pump actuator; and (d) a disposable unit including first and second flexible sheets sealed together for form: (i) at least one flow path configured to be placed in fluid communication with the dilaysate supply; and operable with the at least one valve actuator; and (ii) at least one pumping portion configured to operate with the at least one pump actuator.

Abstract: Systems and methods manually process blood and blood components in sterile, closed environments, which further condition the blood components for subsequent pathogen inactivation processes. The systems and methods mate the manual collection of random donor platelet units with the creation of larger therapeutic doses of platelets targeted to undergo pathogen inactivation prior to long term storage and/or transfusion.

Abstract: A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least one microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Abstract: A fluid processing assembly can be easily inserted into and removed from a rotatable centrifuge assembly.

Abstract: A fluid processing assembly can be easily inserted into and removed from a rotatable centrifuge channel. The processing assembly comprises a processing container and a carrier. The processing container has flexibility and, in use, occupies the channel to receive fluids for separation in the centrifugal field. The carrier retains the processing container outside the channel in a flexed condition conforming to the channel. The carrier resists deformation of the processing container during its insertion into or removal from the channel.

Abstract: A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least on microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Abstract: A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least one microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Abstract: A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least one microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Abstract: Methods and systems for preparing blood products that are ready for treatment in established pathogen inactivation procedures are disclosed. The methods include providing a source of a blood component and combining the blood component with a synthetic medium in a selected ratio of the blood component to the synthetic media, whereby the resulting blood product is treatment-ready.